Year-round
LNP Science Co-op
Posted on 9/3/2025
Beam Therapeutics
501-1,000 employees
Develops base editing–based precision medicines
No salary listed
Cambridge, MA, USA
In Person
 Biology & Biotech (4) |
|---|
| , , , |
- Pursuing a BS or MS in Biology, Biochemistry, Biomedical Engineering, or related field of study with at least 1 year of relevant laboratory experience.
- Must be a team player, comfortable working collaboratively and thriving in a fast-paced environment.
- Proficient in Excel, PowerPoint, and data analysis. Knowledge of GraphPad Prism a plus.
- Experience maintaining a lab notebook and following written protocols.
- Motivated to learn and detail oriented with excellent organizational and communication skills.
- Must be able to be onsite.
- Applicants must be currently enrolled in a degree-granting college or university program and maintain their student status throughout the duration of the co-op to be eligible.
- * Formulate and characterize LNPs to determine size, polydispersity, concentration, encapsulation, and ligand content using established assays and techniques.
- * Participate in platform assay development, including testing of new materials and protocols.
- * Evaluate the delivery of base editor technologies through in vitro and in vivo base editing studies.
- * Document, summarize and present studies and findings to an internal audience at group meetings.
- * Document and manage all experimental planning and results in electronic lab notebook, including statistical analysis and troubleshooting where appropriate.
- * Adhere to all laboratory safety requirements and procedures, assist in maintaining general laboratory functionality, including maintenance of lab equipment and receiving of lab supplies.
Beam Therapeutics uses base editing to develop precision genetic medicines aimed at correcting disease-causing mutations. It focuses on R&D and collaborates with pharmaceutical companies and research institutions to fund and advance therapies, earning revenue through partnerships, licensing, upfront and milestone payments, and royalties. The company targets genetic disorders such as sickle cell disease with the goal of delivering lifelong cures, differentiating itself through its emphasis on durable genetic remedies and a science-driven, values-led culture.
Company Size
501-1,000
Company Stage
IPO
Headquarters
Cambridge, Massachusetts
Founded
2017
Simplify's Take
What believers are saying
- BEAM-302 achieves clinical proof-of-concept in alpha-1 antitrypsin deficiency Phase 1/2 trial.
- $500M Sixth Street credit facility funds risto-cel sickle cell launch by 2027.
- BEACON trial data for BEAM-101 in 17 sickle cell patients presented at EHA2025.
What critics are saying
- CRISPR Therapeutics' Casgevy captures 70% sickle cell market share since December 2024.
- Busulfan conditioning toxicity halts BEAM-101 trial per EHA2025 data.
- Prime Medicine's prime editing outperforms base editing in AATD models per October 2025.
What makes Beam Therapeutics unique
- Beam's base editors precisely convert single DNA bases without double-strand breaks.
- Proprietary cytosine and adenine editors target point mutations in genetic diseases.
- Founded in 2017 by Harvard base editing pioneers for precision genetic medicines.
Help us improve and share your feedback! Did you find this helpful?
Benefits
Flexible Work Hours
Growth & Insights and Company News
6 month growth
↑ 0%1 year growth
↑ 1%2 year growth
↑ 1%Beam Therapeutics CEO John Evans sold 30,078 shares on 1 April 2026 for approximately $739,000, according to an SEC Form 4 filing. The shares were sold at around $24.58 each under a pre-established Rule 10b5-1 trading plan. This sale is smaller than Evans' recent average of 45,200 shares per transaction and represents his smallest open-market sale in his last four disclosed transactions. Following the sale, Evans retains 1,047,205 direct shares and 103,000 indirect shares, maintaining direct ownership of 1.03% of outstanding shares. Beam Therapeutics, valued at $2.79 billion, develops precision genetic medicines using base editing technology, focusing on treatments for sickle cell disease, beta thalassemia and other rare genetic disorders.
Chinese trial backs base-editing drug for thalassaemia. digitale.de A landmark study in China has shown that a base-editing therapy developed by CorrectSequence Therapeutics achieved stellar results in patients with the severe blood disorder beta-thalassaemia. The ex vivo therapy, CS-101, has been tested in an investigator-led trial in five patients with transfusion-dependent beta-thalassemia who received autologous CD34 stem cells modified with the base editor to reactivate the production of a foetal form of haemoglobin. In beta-thalassaemia, mutations in the beta-globin gene mean that patients have deficient production of the adult form of haemoglobin. In severe cases, they have to have blood transfusions every two to five weeks to survive, a burdensome treatment that also places them at risk of complications like iron overload and infections. In the trial, all five patients were able to discontinue transfusions after a single infusion of CS-101-modified stem cells, with rapid and sustained increases in haemoglobin levels over three months of follow-up. Remarkably, patients became transfusion-independent within an average of just 16 days, according to the researchers, who have published their findings in the journal Nature. Shanghai-based CorrectSequence is one of the pioneers of the base-editing approach to gene-editing, which can be used to convert one nucleotide base into another without cutting both strands of DNA, unlike other technologies like CRISPR/Cas9. Theoretically, base-editing should be more accurate and have a reduced risk of off-target changes that could cause side effects. CorrectSequence said that, compared to CRISPR-based therapies for beta-thalassaemia, CS-101 demonstrated "faster activation of foetal haemoglobin, more rapid hematopoietic recovery, and earlier restoration of normal haemoglobin levels." The only gene-editing therapy approved for beta-thalassaemia at present is Vertex Pharma's CRISPR-based Casgevy (exagamglogene autotemcel), which has been cleared in the US and Europe for patients aged 12 and older with transfusion-dependent beta-thalassaemia who lack a suitable donor for stem cell transplant. Donor stem cell transplantation was the only curative option for patients for many years, but its use is limited by donor availability, the risk of immune rejection, and high treatment costs, said CorrectSequence. The company thinks CS-101 - which has now been used to treat around 20 patients in the US and internationally - has the potential to become the world's first approved base-editing therapy. Last year, it also reported encouraging clinical results in a patient with chylomicronaemia treated with its CS-121 base editor targeting the APOC3 gene. Other companies working on base-editing technologies include Beam Therapeutics of the US, which is developing a similarly acting ex vivo therapy for sickle cell disease (SCD), called ristoglogene autogetemcel, that showed efficacy in a phase 1/2 trial published in the New England Journal of Medicine earlier this month and could be submitted for FDA approval before the end of the year.
Beam Therapeutics has secured a $500 million senior secured credit facility with Sixth Street to support the anticipated launch of ristoglogene autogetemcel (risto-cel) for sickle cell disease. The agreement includes $100 million funded at close, up to $300 million available upon clinical, regulatory and commercial milestones, and an additional $100 million at Beam's option. The facility has a seven-year term maturing in early 2033, with an annual interest rate of approximately 10% based on SOFR. No scheduled amortization payments are required, with all principal due at maturity. Beam expects to draw at least $200 million under the facility. The financing provides non-dilutive capital to support risto-cel's commercialisation whilst allowing Beam to direct resources towards pipeline growth and developing precision genetic medicines.
Beam Therapeutics to present at 44th Annual J.P. Morgan Healthcare Conference. Beam Therapeutics +1.33% CAMBRIDGE, Mass., Dec. 18, 2025 (GLOBE NEWSWIRE) - Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that John Evans, chief executive officer of Beam, will present at the 44th Annual J.P. Morgan Healthcare Conference on Tuesday, January 13, 2026, at 5:15 p.m. PT in San Francisco. The live webcast will be available in the investor section of the company's website at www.beamtx.com and will be archived for 60 days following the presentation. About Beam Therapeutics Beam Therapeutics (Nasdaq: BEAM) is a biotechnology company committed to establishing the leading, fully integrated platform for precision genetic medicines. To achieve this vision, Beam has assembled a platform with integrated gene editing, delivery and internal manufacturing capabilities. Beam's suite of gene editing technologies is anchored by base editing, a proprietary technology that is designed to enable precise, predictable and efficient single base changes, at targeted genomic sequences, without making double-stranded breaks in the DNA. This has the potential to enable a wide range of therapeutic editing strategies that Beam is using to advance a diversified portfolio of base editing programs. Beam is a values-driven organization committed to its people, cutting-edge science, and a vision of providing life-long cures to patients suffering from serious diseases. Holly Manning Beam Therapeutics [email protected] This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.
Beam Therapeutics (NASDAQ: BEAM), a biotechnology firm pioneering precision genetic medicines via base editing, announced it will present updated data from its BEACON Phase 1/2 trial of BEAM-101 at the European Hematology Association 2025 Congress, June 12-15 in Milan. BEAM-101 is an investigational, one-time ex vivo cell therapy targeting severe vaso-occlusive crises in sickle cell disease (SCD). The new data, covering safety and efficacy outcomes in 17 patients, will be highlighted during multiple poster sessions on June 13, underscoring BEAM-101’s potential to provide a durable treatment by addressing the root cause of SCD. Additional presentations will explore biomarkers, manufacturing advances, and red blood cell health post-treatment. Beam will also host a webcast on June 13 at 4:00 p.m. ET to review EHA highlights. To view the full press release, visit https://nnw.fm/taUAe About Beam Therapeutics Beam Therapeutics (NASDAQ: BEAM) is a biotechnology company committed to establishing the leading, fully integrated platform for precision genetic medicines